Myciguent (neomycin topical) Disease Interactions
There are 2 disease interactions with Myciguent (neomycin topical):
Neomycin (otic) (applies to Myciguent) perforated tympanic membrane
Major Potential Hazard, High plausibility.
Like other aminoglycosides, neomycin is potentially ototoxic, both to vestibular and to auditory functions. Therapy with neomycin otic preparations should be administered cautiously in patients with chronic otitis media or a perforated tympanic membrane. The risk of ototoxicity may be increased if medication enters the middle ear.
- "Product Information. Mycifradin (neomycin)." Emerson Laboratories, Texarkana, TX.
Topical aminoglycosides (applies to Myciguent) burns
Moderate Potential Hazard, High plausibility. Applicable conditions: Burns - External
Topical aminoglycosides should not be used on serious burns. When applied locally, aminoglycosides are generally not absorbed to a significant extent through intact skin but readily absorbed through denuded, burned, or granulating skin. Systemic adverse effects of aminoglycosides include nephrotoxicity and ototoxicity to vestibular and auditory functions. In general, topical aminoglycosides should not be used on large areas of the body or for more than 7 days without medical supervision.
- "Product Information. Myciguent (neomycin topical)." Pharmacia and Upjohn, Kalamazoo, MI.
Myciguent (neomycin topical) drug interactions
There are 21 drug interactions with Myciguent (neomycin topical)
More about Myciguent (neomycin topical)
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Interactions
- Drug class: topical antibiotics
Related treatment guides
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No interaction information available.|